Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | Optimal diagnostic pathway in mesothelioma

Kevin Blyth • 26 Apr 2023
BTOG 2023
Lung Cancer Mesothelioma

Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, discusses the optimal diagnostic pathway in mesothelioma in the UK, highlighting the importance of accurate actionable information such as detailed histological subtype which can help determine whether immune checkpoint inhibition is suitable, good symptom control, as well as support from nurse specialists. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Rocket Medical and Asbestos Action. Received fees for advisory boards from Rocket Medical, Lily and BMS. Trustee of Mesothelioma UK.

More from Kevin Blyth

1:28
Are rates of mesothelioma declining within the UK?
Kevin Blyth • 26 Apr 2023
1:28
Are rates of mesothelioma declining within the UK?
Kevin Blyth • 26 Apr 2023
0:47
Key radiology highlights at BTOG 2023
Kevin Blyth • 27 Apr 2023
0:47
Key radiology highlights at BTOG 2023
Kevin Blyth • 27 Apr 2023

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals